secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009722
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam reports $1.25B cash, FDA alignment on BEAM-302 accelerated path; risto-cel BLA expected year-end 2026
--------------------------------------------------------------------------------

- Estimated $1.25B cash, cash equivalents and marketable securities as of Dec 31, 2025; operating runway extended into 2029.
- FDA alignment on potential accelerated approval for BEAM-302 based on AAT biomarkers over 12 months; ~50 additional patients to be enrolled.
- BLA submission for risto-cel (formerly BEAM-101) expected as early as year-end 2026; BEACON trial fully enrolled, manufacturing done December 2025.
- Updated BEAM-302 Phase 1/2 data and pivotal plan expected by end of Q1 2026; new liver-targeted program to be announced H1 2026.
- Initial BEAM-301 clinical data expected in 2026; BEAM-103 Phase 1 healthy volunteer trial to complete dosing in H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312526009722/0001193125-26-009722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312526009722/beam-20260111.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer